Baidu
map

Expert Rev Ophthalmol:BDNF/TrkB信号通路在视觉系统中的作用:对青光眼的治疗意义!

2017-07-31 cuiguizhong MedSci原创

美国奥古斯塔大学眼科系的Bollinger KE教授近日在Korean J Ophthalmol杂志上发表了一篇综述,系统的阐述了BDNF / TrkB信号通路在青光眼发展过程的作用,并对其治疗提出展望。

美国奥古斯塔大学眼科系的Bollinger KE教授近日在Korean J Ophthalmol杂志上发表了一篇综述,系统的阐述了BDNF / TrkB信号通路在青光眼发展过程的作用,并对其治疗提出展望。

青光眼是一种视神经病变,它可以引起视网膜神经节细胞(RGC)的死亡。因此,针对青光眼的治疗需要进行神经保护治疗。

BDNF / TrkB途径对视网膜神经节细胞(RGC)的存活具有很重要的作用。在急性视神经损伤和青光眼发育过程中, BDNF / TrkB通路具有时空变化的特征。在动物模型实验中,患急性视神经损伤和青光眼后,提高BDNF可以减少视网膜神经节细胞(RGC)的死亡。然而,对于视网膜神经节细胞(RGC)的长期存活,BDNF / TrkB信号通路并不是唯一信号通路。

有专家评论称,关于神经元和神经胶质细胞中逆行视神经、顺行视神经和视网膜中BDNF / TrkB信号通路之间的相互作用还有待深入研究。治疗青光眼的理想药物应具有多种作用模式,可以靶向多种神经退行性疾病的发病机制,这其中包括BDNF / TrkB途径。这项工作给青光眼的治疗带来了新的启发。

原文出处:

Mysona, B.A., J. Zhao, and K.E. Bollinger, Role of BDNF/TrkB pathway in the visual system: Therapeutic implications for glaucoma. Expert Rev Ophthalmol, 2017. 12(1): p. 69-81.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-09-14 Tamikia
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2018-05-31 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-08-02 apoenzyme
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-08-02 zywlvao
  6. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1953597, encodeId=90d4195359e49, content=<a href='/topic/show?id=5ba26462383' target=_blank style='color:#2F92EE;'>#治疗意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64623, encryptionId=5ba26462383, topicName=治疗意义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af68384, createdName=hanhaisha2008, createdTime=Fri Dec 01 14:43:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780291, encodeId=0b311e802914f, content=<a href='/topic/show?id=b1df3300c8' target=_blank style='color:#2F92EE;'>#BDNF/TrkB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3300, encryptionId=b1df3300c8, topicName=BDNF/TrkB)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Jr8S1dfvNyP22t32IFDXJXnpd5AGlDibiajL5cl3pxj7OPCeAeibLhzOmZn5Q2Oicc6uKOCnxGNOggdLtI3hIW7huQ/132, createdBy=66e52500008, createdName=Tamikia, createdTime=Thu Sep 14 07:43:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726612, encodeId=1cd41e266123b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu May 31 07:43:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423842, encodeId=539c1423842d8, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481079, encodeId=9d5114810e9a2, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539619, encodeId=7ba8153961928, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541253, encodeId=a5a8154125310, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Aug 02 03:43:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228520, encodeId=ba2122852052, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jul 31 17:58:49 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-07-31 131****1460

    学习了受益匪浅。

    0

相关资讯

J Glaucoma. :饮水测试的眼内压峰值可以预测青光眼视觉发展情况!

哥伦比亚大学医学中心眼科的De Moraes CG在J Glaucoma.发表了一项工作,他们这项工作的目的是测试他们提出的一个假设:在压力测试时[饮水测试(WDT)],眼内压(IOP)峰值可以用来预测经过治疗的原发性开角型青光眼(POAG)患者未来视野恢复过程中的风险。

我国微导管辅助的360°小梁切开术专家共识(2017年)

微导管辅助的360。小梁切开术是在黏小管成形术基础上发展起来的新术式,是在直视下将发光微导管准确插入Schlernm管内,实现360。穿通,然后利用微导管将Schlemm管内壁及小梁网360。切开。该技术可避免常规手术切开刀未进入Schlemm管而造成假道形成等并发症的发生”。 为了临床能够正确开展微导管辅助的360。小梁切开术,中华医学会眼科学分会青光眼学组全体委员通过认真讨论,对手术提出以下共

我国房水流出通路重建术专家共识(2017年)

为了临床能够正确开展房水流出通路重建术,中华医学会眼科学分会青光眼学组全体委员通过认真讨论,对手术提出该共识意见。

PLoS One. :增强的深度成像光学相干断层扫描发现不同疾病阶段青光眼患者视神经结特征变化!

巴西圣保罗圣保罗联邦大学眼科系Paranhos A Jr教授近日在PLoS One.杂志上发表了他们的一项重要工作,他们通过增强的深度成像光学相干断层扫描,发现不同疾病阶段青光眼患者视神经结特征变化!

我国复合式小梁切除术操作专家共识(2017年)

经过几十年的发展,将可拆除缝线技术、抗代谢药物、前房穿刺技术及术中对术后滤过量的预评估等方法应用于小梁切除术,使传统的小梁切除术逐渐演变为现在的复合式小梁切除术。为了进一步规范手术操作,指导临床工作,提高手术疗效,中华医学会眼科学分会青光眼学组经过认真讨论,现对复合式小梁切除术操作提出以下共识意见,以供大家参考使用。

Graefes Arch Clin Exp Ophthalmol:药物治疗不佳的青光眼患者使用rho激酶抑制剂Ripasudil进行辅助性治疗一年后疗评估

日本横滨市立大学医学部眼科与微观科学系 Kadonosono K教授近日在Graefes Arch Clin Exp Ophthalmol.发表了他们的一项重要工作,他们了在评估在药物治疗不理想的青光眼患者中,使用一种rho激酶抑制剂治疗一年后的效果,降低眼内压的能力,以及ripasudil的耐受性。

Baidu
map
Baidu
map
Baidu
map